Azimilide vs. placebo and sotalol for persistent atrial fibrillation: The A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial

Federico Lombardi, Martin Borggrefe, Witold Ruzyllo, Berndt Lüderitz

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Aims: Treatment of atrial fibrillation remains a major clinical challenge owing to the limited efficacy and safety of anti-arrhythmic drugs, particularly in patients with structural heart disease. Methods and results: To evaluate the efficacy of azimilide, a new class III anti-arrhythmic drug, we studied 658 patients with symptomatic persistent atrial fibrillation, adequate anticoagulant therapy, and planned electrical cardioversion. Patients were randomized to placebo, azimilide (125 mg o.d.), or sotalol (160 mg b.i.d.). Primary efficacy analysis was based on event recurrence, which was defined as atrial fibrillation lasting > 24 h, or requiring DC cardioversion. Median time to recurrence was 14 days for azimilide, 12 days for placebo, and 28 days for sotalol (P = 0.0320 when comparing azimilide with placebo; P = 0.0002 when comparing azimilide with sotalol). The placebo-to-azimilide hazard ratio was 1.291 (95% CI: 1.022-1.629) and the sotalol-to-azimilide hazard ratio was 0.652 (95% CI: 0.523-0.814). Adverse events causing patient withdrawal were more frequent (P <0.01) in patients on azimilide (12.3%) and on sotalol (13.9%) than on placebo (5.4%). Eight patients in the sotalol (3.5%) and 16 in the azimilide (7.6%) group interrupted the study because of QTc prolongation. Torsade de pointes was reported in five patients of the azimilide group. The percentage of patients who completed the 26 week study period without events were 19% for azimilide, 15% for placebo, and 33% for sotalol (P <0.01). Unsuccessful day 4 cardioversion, arrhythmia recurrence, and adverse events were the main causes of withdrawal from the study. Conclusion: This study demonstrates that the anti-arrhythmic efficacy of azimilide is slightly superior to placebo but significantly inferior to sotalol in patients with persistent AF. The modest anti-arrhythmic efficacy and high rate of torsade de pointes and marked QTc prolongation limit azimilide utilization for the treatment of AF.

Original languageEnglish
Pages (from-to)2224-2231
Number of pages8
JournalEuropean Heart Journal
Volume27
Issue number18
DOIs
Publication statusPublished - Sep 2006

Fingerprint

Sotalol
Electric Countershock
Atrial Fibrillation
Placebos
Anti-Arrhythmia Agents
Torsades de Pointes
Recurrence
azimilide
Pharmaceutical Preparations
Anticoagulants
Cardiac Arrhythmias

Keywords

  • Anti-arrhythmic drugs
  • Atrial fibrillation
  • Long QT
  • Torsade de pointes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Azimilide vs. placebo and sotalol for persistent atrial fibrillation : The A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial. / Lombardi, Federico; Borggrefe, Martin; Ruzyllo, Witold; Lüderitz, Berndt.

In: European Heart Journal, Vol. 27, No. 18, 09.2006, p. 2224-2231.

Research output: Contribution to journalArticle

@article{ec741763c4fc4528b87a25537710e09d,
title = "Azimilide vs. placebo and sotalol for persistent atrial fibrillation: The A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial",
abstract = "Aims: Treatment of atrial fibrillation remains a major clinical challenge owing to the limited efficacy and safety of anti-arrhythmic drugs, particularly in patients with structural heart disease. Methods and results: To evaluate the efficacy of azimilide, a new class III anti-arrhythmic drug, we studied 658 patients with symptomatic persistent atrial fibrillation, adequate anticoagulant therapy, and planned electrical cardioversion. Patients were randomized to placebo, azimilide (125 mg o.d.), or sotalol (160 mg b.i.d.). Primary efficacy analysis was based on event recurrence, which was defined as atrial fibrillation lasting > 24 h, or requiring DC cardioversion. Median time to recurrence was 14 days for azimilide, 12 days for placebo, and 28 days for sotalol (P = 0.0320 when comparing azimilide with placebo; P = 0.0002 when comparing azimilide with sotalol). The placebo-to-azimilide hazard ratio was 1.291 (95{\%} CI: 1.022-1.629) and the sotalol-to-azimilide hazard ratio was 0.652 (95{\%} CI: 0.523-0.814). Adverse events causing patient withdrawal were more frequent (P <0.01) in patients on azimilide (12.3{\%}) and on sotalol (13.9{\%}) than on placebo (5.4{\%}). Eight patients in the sotalol (3.5{\%}) and 16 in the azimilide (7.6{\%}) group interrupted the study because of QTc prolongation. Torsade de pointes was reported in five patients of the azimilide group. The percentage of patients who completed the 26 week study period without events were 19{\%} for azimilide, 15{\%} for placebo, and 33{\%} for sotalol (P <0.01). Unsuccessful day 4 cardioversion, arrhythmia recurrence, and adverse events were the main causes of withdrawal from the study. Conclusion: This study demonstrates that the anti-arrhythmic efficacy of azimilide is slightly superior to placebo but significantly inferior to sotalol in patients with persistent AF. The modest anti-arrhythmic efficacy and high rate of torsade de pointes and marked QTc prolongation limit azimilide utilization for the treatment of AF.",
keywords = "Anti-arrhythmic drugs, Atrial fibrillation, Long QT, Torsade de pointes",
author = "Federico Lombardi and Martin Borggrefe and Witold Ruzyllo and Berndt L{\"u}deritz",
year = "2006",
month = "9",
doi = "10.1093/eurheartj/ehl209",
language = "English",
volume = "27",
pages = "2224--2231",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "18",

}

TY - JOUR

T1 - Azimilide vs. placebo and sotalol for persistent atrial fibrillation

T2 - The A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial

AU - Lombardi, Federico

AU - Borggrefe, Martin

AU - Ruzyllo, Witold

AU - Lüderitz, Berndt

PY - 2006/9

Y1 - 2006/9

N2 - Aims: Treatment of atrial fibrillation remains a major clinical challenge owing to the limited efficacy and safety of anti-arrhythmic drugs, particularly in patients with structural heart disease. Methods and results: To evaluate the efficacy of azimilide, a new class III anti-arrhythmic drug, we studied 658 patients with symptomatic persistent atrial fibrillation, adequate anticoagulant therapy, and planned electrical cardioversion. Patients were randomized to placebo, azimilide (125 mg o.d.), or sotalol (160 mg b.i.d.). Primary efficacy analysis was based on event recurrence, which was defined as atrial fibrillation lasting > 24 h, or requiring DC cardioversion. Median time to recurrence was 14 days for azimilide, 12 days for placebo, and 28 days for sotalol (P = 0.0320 when comparing azimilide with placebo; P = 0.0002 when comparing azimilide with sotalol). The placebo-to-azimilide hazard ratio was 1.291 (95% CI: 1.022-1.629) and the sotalol-to-azimilide hazard ratio was 0.652 (95% CI: 0.523-0.814). Adverse events causing patient withdrawal were more frequent (P <0.01) in patients on azimilide (12.3%) and on sotalol (13.9%) than on placebo (5.4%). Eight patients in the sotalol (3.5%) and 16 in the azimilide (7.6%) group interrupted the study because of QTc prolongation. Torsade de pointes was reported in five patients of the azimilide group. The percentage of patients who completed the 26 week study period without events were 19% for azimilide, 15% for placebo, and 33% for sotalol (P <0.01). Unsuccessful day 4 cardioversion, arrhythmia recurrence, and adverse events were the main causes of withdrawal from the study. Conclusion: This study demonstrates that the anti-arrhythmic efficacy of azimilide is slightly superior to placebo but significantly inferior to sotalol in patients with persistent AF. The modest anti-arrhythmic efficacy and high rate of torsade de pointes and marked QTc prolongation limit azimilide utilization for the treatment of AF.

AB - Aims: Treatment of atrial fibrillation remains a major clinical challenge owing to the limited efficacy and safety of anti-arrhythmic drugs, particularly in patients with structural heart disease. Methods and results: To evaluate the efficacy of azimilide, a new class III anti-arrhythmic drug, we studied 658 patients with symptomatic persistent atrial fibrillation, adequate anticoagulant therapy, and planned electrical cardioversion. Patients were randomized to placebo, azimilide (125 mg o.d.), or sotalol (160 mg b.i.d.). Primary efficacy analysis was based on event recurrence, which was defined as atrial fibrillation lasting > 24 h, or requiring DC cardioversion. Median time to recurrence was 14 days for azimilide, 12 days for placebo, and 28 days for sotalol (P = 0.0320 when comparing azimilide with placebo; P = 0.0002 when comparing azimilide with sotalol). The placebo-to-azimilide hazard ratio was 1.291 (95% CI: 1.022-1.629) and the sotalol-to-azimilide hazard ratio was 0.652 (95% CI: 0.523-0.814). Adverse events causing patient withdrawal were more frequent (P <0.01) in patients on azimilide (12.3%) and on sotalol (13.9%) than on placebo (5.4%). Eight patients in the sotalol (3.5%) and 16 in the azimilide (7.6%) group interrupted the study because of QTc prolongation. Torsade de pointes was reported in five patients of the azimilide group. The percentage of patients who completed the 26 week study period without events were 19% for azimilide, 15% for placebo, and 33% for sotalol (P <0.01). Unsuccessful day 4 cardioversion, arrhythmia recurrence, and adverse events were the main causes of withdrawal from the study. Conclusion: This study demonstrates that the anti-arrhythmic efficacy of azimilide is slightly superior to placebo but significantly inferior to sotalol in patients with persistent AF. The modest anti-arrhythmic efficacy and high rate of torsade de pointes and marked QTc prolongation limit azimilide utilization for the treatment of AF.

KW - Anti-arrhythmic drugs

KW - Atrial fibrillation

KW - Long QT

KW - Torsade de pointes

UR - http://www.scopus.com/inward/record.url?scp=33748775202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748775202&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehl209

DO - 10.1093/eurheartj/ehl209

M3 - Article

C2 - 16935870

AN - SCOPUS:33748775202

VL - 27

SP - 2224

EP - 2231

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 18

ER -